Artemis Medicare Services Ltd
Artemis Medicare Services Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Artemis Medicare anticipates a 15% to 17% annual revenue growth from flagship hospitals over the next 3-4 years. Revenue growth of 15% to 17% year-on-year expected from flagship hospitals over next 3-4 years (Rudra Acharjee, Pg 16). - At least 30% of incremental revenue expected to flow down to EBITDA (Pg 16). - Gurgaon hospital EBITDA margin projected north of 20%, driven by improved patient mix, operational efficiency, and cost sharing across facilities (Pg 10). - EBITDA margin for Gurgaon was 21.3% in Q4 FY26, with efforts to maintain or improve margins in FY27 (Pg 7, 10). - Raipur facility expected to incur losses of INR 18-20 crores initially, impacting consolidated EBITDA by 1-1.5% for 15-18 months, then contributing positively (Pg 16, 7). - Free cash flow improving: INR 88 crores in FY26 vs.
From Artemis Medicare Services Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Artemis Medicare anticipates a 15% to 17% annual revenue growth from flagship hospitals over the next 3-4 years.
- Expansion plans include increasing operational beds from 544 currently and adding 200 beds at Raipur, targeting 2,000+ beds by 2029.
- International patient revenue is expected to remain around 30-31%, with ongoing geographic diversification.
- The Gurgaon facility aims to increase occupancy from ~64.6% to 70-75% by Q2 FY27, supporting revenue growth.
- A 15% overall increase in top line is budgeted for both domestic and international patients, with price hikes of about 15%.
- Raipur facility is expected to break even within 15-18 months of operation, with initial losses offset by growth in Gurgaon.
- ARPOB is projected to grow 7%-8% year-on-year, driven by high-end surgeries and improved efficiencies.
Profitability & Margins
See what Artemis Medicare Services Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Gurgaon: Potential addition of 100 beds; plan to open 50 beds once 70% occupancy is achieved, followed by another 50 beds; capital allocation focusing on extension and maturity of existing towers.
- New South Delhi & Raipur facilities:
- - Raipur: 650-bed facility planned in two phases (450 beds and 200 beds); capex around INR 500 crores (INR 350 crores for first 450 beds, INR 150-160 crores for next 200 beds); interiors and equipment included; Raipur operational beds to reach 300 within two quarters post-launch.
- - South Delhi: 650 beds planned; capex to start post-FY27 with major expenses from FY28 onwards; includes interiors and equipment, land/building owned by trust.
- Additional capex of INR 100 crores planned in FY27 for Gurgaon replacement and fitting for Raipur.
- Capital raise target of INR 700 crores approved by board for funding new projects beyond currently announced ones, including deposits not fundable by debt.
- Focus on projects with target ROCE of 16-18% and payback within 5-6 years.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Artemis Medicare Services Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Artemis Medicare Services Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹274 Cr, net profit ₹30 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Artemis Medicare's management said in earlier quarters
Others in Healthcare Services this season
- Apollo Hospitals (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
- Health X Platform (Q4 FY26)
Northeast operations growing 50%+ year-on-year and Northern India 25–30%, with plans for 5–7% market share in 2-3 years (Page 10). Key concall takeaways from…
- Park Medi World (Q4 FY26)
Total planned capex for the next two years is around INR 500 crores. Key concall takeaways from Park Medi World's Q4 FY26 earnings call — and how it ranks…
- Vimta Labs Ltd (Q4 FY26)
. Key concall takeaways from Vimta Labs Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Artemis Medicare Services Ltd Q4 FY26 results?
Artemis Medicare anticipates a 15% to 17% annual revenue growth from flagship hospitals over the next 3-4 years. Revenue growth of 15% to 17% year-on-year expected from flagship hospitals over next 3-4 years (Rudra Acharjee, Pg 16). - At least 30% of incremental revenue expected to flow down to EBITDA (Pg 16). - Gurgaon hospital EBITDA margin projected north of 20%, driven by improved patient mix, operational efficiency, and cost sharing across facilities (Pg 10). - EBITDA margin for Gurgaon was 21.3% in Q4 FY26, with efforts to maintain or improve margins in FY27 (Pg 7, 10). - Raipur facility expected to incur losses of INR 18-20 crores initially, impacting consolidated EBITDA by 1-1.5% for 15-18 months, then contributing positively (Pg 16, 7). - Free cash flow improving: INR 88 crores in FY26 vs.
What is Artemis Medicare Services Ltd share price analysis?
Artemis Medicare Services Ltd currently shows a neutral. The stock trades at a P/E of 44.2 with a market cap of ₹5,100 Cr. Investors should review the full earnings analysis for detailed insights.
Is Artemis Medicare Services Ltd planning capital expenditure?
Gurgaon: Potential addition of 100 beds; plan to open 50 beds once 70% occupancy is achieved, followed by another 50 beds; capital allocation focusing on extension and maturity of existing towers.
Keep Artemis Medicare Services Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.